Table 1.
Demographic and clinical characteristics of study participants.
| Characteristics | MUD group (N = 26) | HC group (N = 17) | P-value |
|---|---|---|---|
| Age, years | 33.34 [31.80-38.17] | 34.00 [26.5-55.5] | 0.619a |
| BMI, kg/m2 | 24.92 ± 3.06 | 23.63 ± 3.73 | 0.222b |
| Education, years | 12 [9-14.25] | 16 [9-17] | 0.188a |
| Married, N (%) | 7 (26.9%) | 10 (58.8%) | 0.036c |
| Employed, N (%) | 21 (80.8%) | 17 (100%) | 0.139d |
| AUDIT | 9 [0-13.25] | 0 [0-0] | <0.001a |
| FTND | 5 [2.75-6] | 0 [0-1] | <0.001a |
| METH use characteristics | |||
| Age of first use | 27.47 ± 5.33 | NA | NA |
| Total years of use | 4 [3-7] | NA | NA |
| Months of abstinence | 8.22 [3.38-16.04] | NA | NA |
| Frequency of use (in last month before rehabilitation) | NA | ||
| Almost everyday | 0 (0%) | – | |
| 3-5 times a week | 4 (15.4%) | – | |
| 1-2 times a week | 8 (30.8%) | – | |
| Less than once a week | 14 (53.8%) | – | |
| Craving (VAS) | 2 [0.5-4.35] | – | |
| Emotion | |||
| PHQ-9 | 3 [0.75-5] | – | NA |
| GAD-7 | 1 [0-4.25] | – | NA |
| Inflammatory markers | |||
| CRP, mg/L | 7.72 ± 1.66 | – | NA |
| TNF-α, pg/mL | 69.88 ± 12.11 | – | NA |
| IL-2, ng/mL | 6.84 ± 1.50 | – | NA |
| IL-6, pg/mL | 27.01 ± 7.41 | – | NA |
| IL-10, pg/mL | 937.21 ± 169.26 | – | NA |
Data are presented as mean ± standard deviation (SD), Median [IQR, inter-quartile range], or N (%). ap values based on Mann-Whitney U test; bp values based on Student’s t test; cp values based on Pearson chi-square test; dp values based on Fisher exact test. MUD, methamphetamine use disorder; HC, healthy control; BMI, body mass index, calculated as weight in kilograms divided by height in meters squared; AUDIT= Alcohol Use Disorders Identification Test; FTND, Fagerstrom Test for Nicotine Dependence; NA, not applicable; VAS, Visual Analogue Scale; PHQ-9, Patient Health Questionnaire-9; GAD-7, General Anxiety Disorder Scale-7; CRP, C-reactive protein; TNF-α, Tumor necrosis factor-alpha; IL, Interleukin.